Rituximab-induced remission in CIDP (ReCIX study)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512506-25-00

Enrollment

102

Registered

2024-08-15

Start date

2024-10-07

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Brief summary

Remission at 52 weeks after start of RTX, i.e., no need of additional treatment after RTX treatment.

Detailed description

Stability on treatment at 104 weeks of follow-up.

Interventions

DRUGRixathon 500 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Remission at 52 weeks after start of RTX, i.e., no need of additional treatment after RTX treatment.	—

Secondary

Measure	Time frame
Stability on treatment at 104 weeks of follow-up.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026